First US Generic Launch Date
The US market saw the first generic version of ruxolitinib (the active ingredient in Jakafi) launch on February 17, 2023. This followed a settlement between Incyte Corp., the brand's developer, and generic maker Aurobindo Pharma, allowing early entry after FDA tentative approval. Aurobindo's ANDA for the 5 mg, 15 mg, and 20 mg tablets received final approval that day, marking the initial generic availability.[1][2]
Why the Delay Until 2023?
Ruxolitinib's brand exclusivity stemmed from Incyte's New Chemical Entity status (NCE) until February 2022, plus pediatric exclusivity extending to August 2022. Patents listed in the FDA's Orange Book, including US Patent 7,598,257 (expiring 2027), were challenged via Paragraph IV certifications, leading to litigation. The Aurobindo settlement resolved this for early entry, but core patents remain active.[3][4]
Which Companies Launched Generics First?
Aurobindo Pharma (including subsidiaries Aurobindo Pharma Ltd. and Currax Pharmaceuticals) was first, with tablets in 5 mg, 10 mg, 15 mg, and 20 mg strengths. Sandoz followed shortly after with its own launch in March 2023. Multiple ANDAs (over 10) are approved or pending from firms like Dr. Reddy's, Apotex, and Sunshine Lake.[1][5]
Impact on Pricing and Availability
Generics entered at discounts of 80-90% off Jakafi's list price (around $15,000/month pre-generic). By mid-2023, they captured over 50% market share, though Incyte retains branded dominance via authorized generics and patient assistance. Check DrugPatentWatch.com for real-time patent challenges and entry dates: DrugPatentWatch - Ruxolitinib.[2][6]
When Do Remaining Patents Expire?
Key Orange Book patents expire between 2025 (formulation patents) and 2031 (method-of-use). Litigation continues; for example, Natco and others challenge remaining barriers. Full generic competition may not peak until 2027-2028 absent further settlements.[4]
Clinical Equivalence and Patient Switch
FDA deems generics bioequivalent to Jakafi, with identical labeling for myelofibrosis, polycythemia vera, and graft-versus-host disease. Patients report seamless switches, but monitor for rare hypersensitivity differences.[7]
Sources:
[1] FDA ANDA Approvals Database - https://www.accessdata.fda.gov/scripts/cder/ob/resultsproduct.cfm
[2] DrugPatentWatch - https://www.drugpatentwatch.com/p/generic-api/RUXOLITINIB
[3] FDA Orange Book - https://www.accessdata.fda.gov/scripts/cder/ob/
[4] USPTO Patent Database - https://patents.google.com/patent/US7598257
[5] Sandoz Press Release, March 2023 - https://www.sandoz.com/news/media-releases
[6] IQVIA Market Data, 2023
[7] FDA Labeling - https://www.accessdata.fda.gov/drugsatfdadocs/label/2023/